21.34
-0.4(-1.84%)
Currency In CNY
Address
Hanyu Biological Park, No. 37
Shenzhen, 518057
China
Phone
86 755 2658 8000
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
895
First IPO Date
April 07, 2011
| Name | Title | Pay | Year Born |
| Ms. Di Yang | Vice President, Secretary & Director | 0 | 1985 |
| Mr. Honghong Tu | Vice President, Chief Financial Officer & Accounting Supervisor | 0 | 1976 |
| Ms. Min Zhang | Vice President | 0 | 1980 |
| Mr. Heng Quan | Vice President of Human Resource & Administration Department | 0 | N/A |
| Mr. Yu Liu | Vice President of Marketing | 0 | N/A |
| Ms. Yu Pinxiang | Executive President & Director | 0 | 1973 |
| Mr. Zhaohui Zeng | Vice President | 0 | 1974 |
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.